This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2023
Presentations

Session Info Card
Session Info Card

Tisotumab Vedotin | Cervical Cancer | Abstract #LBA9
innovaTV 301/ENGOT-cx12/GOG-3057: a randomized, open-label, phase 3 study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Enfortumab Vedotin | Urothelial Cancer | Abstract #LBA6
EV-302/KEYNOTE-A39: Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Enfortumab Vedotin | Bladder Cancer | Abstract #813
Study EV-103 Cohort L: perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Tucatinib | Colorectal Cancer | Abstract #857
Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER

Tucatinib | Gastroesophageal Cancer | Abstract #1914
Phase 2 dose optimization results from MOUNTAINEER-02: a study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)

SGN-B7H4V | Solid Tumors | Abstract #1546
First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase 1 study (SGNB7H4V-001)